Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study코로나바이러스 질병 2019(COVID-19)에 대한 정신 장애 및 하이드록시클로로퀸: VigiBase 연구Article Published on 2020-12-012022-09-11 Journal: Drug safety [Category] 진단, 치료제, [키워드] 95% CI 95% confidence interval Adverse drug reaction Adverse drug reactions adverse effect adverse effects Analysis analyzed calculate Cardiomyopathy cause of death CIs coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pandemic COVID-19 patient COVID-19 patients database death disorder followed by Health Organization Hydroxychloroquine increased risk indication indications Lopinavir Lopinavir/ritonavir Odds ratio Odds ratios pandemic patients performed Psychiatric psychiatric disorder Psychiatric disorders psychotic disorders raised Remdesivir reported Respiratory failure risk Ritonavir safety profile second Suicide Tocilizumab use of hydroxychloroquine WHO World Health Organization [DOI] 10.1007/s40264-020-01013-3 PMC 바로가기 [Article Type] Article
1,2,4 triazolo[1,5-a] pyrimidin-7-ones as novel SARS-CoV-2 Main protease inhibitors: In silico screening and molecular dynamics simulation of potential COVID-19 drug candidates새로운 SARS-CoV-2 주요 프로테아제 억제제로서의 1,2,4 트리아졸로[1,5-a] 피리미딘-7-온: 잠재적인 COVID-19 약물 후보의 인실리코 스크리닝 및 분자 역학 시뮬레이션Article Published on 2020-12-012022-09-12 Journal: Biophysical chemistry [Category] MERS, SARS, 진단, [키워드] 1,2,4 triazolo[1,5-a] pyrimidin-7-one amino acid residue Antiviral binding affinity binding energy complexes Compound compounds COVID-19 Cys145 deviation drug candidate evidenced fluctuation Glu166 high affinity His41 inhibitor less Lopinavir M pro molecular docking molecular dynamics Molecular dynamics simulation Molecular mechanics nelfinavir novel Novel antiviral compound positive controls protease Protease inhibitor radius of gyration SARS-CoV-2 SARS-CoV-2 main protease SARS-CoV-2 Main protease inhibitor. screened Toxicity ZINC database [DOI] 10.1016/j.bpc.2020.106478 PMC 바로가기 [Article Type] Article
Targeting the coronavirus SARS-CoV-2: computational insights into the mechanism of action of the protease inhibitors lopinavir, ritonavir and nelfinavir코로나바이러스 SARS-CoV-2 표적화: 프로테아제 억제제 로피나비르, 리토나비르 및 넬피나비르의 작용 기전에 대한 컴퓨터 통찰력Article Published on 2020-12-012022-09-10 Journal: Scientific Reports [Category] SARS, 신약개발, 치료제, [키워드] atomic level Betacoronavirus Chinese health authorities Clinical use coronavirus coronavirus disease Coronavirus disease 2019 coronavirus SARS-CoV-2 crystallographic structure Drug discovery drugs effective endopeptidase Final health authorities HIV/AIDS In-vitro Infectious diseases information inhibitors lack Ligand Lopinavir LOPINAVIR AND RITONAVIR M pro mechanism of action Medicinal chemistry molecular molecular dynamics nelfinavir pathway protease Protease inhibitor provided Research respiratory Respiratory disease responsible Ritonavir RNA SARS-CoV SARS-CoV-2 SARS-CoV-2 main protease severe respiratory disease shown single-stranded starting targeting the SARS-CoV-2 therapeutic strategy Treatment Viral viral infection [DOI] 10.1038/s41598-020-77700-z PMC 바로가기 [Article Type] Article
Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2′s main proteaseResearch Published on 2020-11-262022-10-28 Journal: Virology Journal [Category] COVID-19, SARS, [키워드] acting acute respiratory syndrome Antiviral assays carried caused Cell culture cell culture experiment Concentration coronavirus COVID-19 cytotoxicity drug effective Efficacy enzymatic assay GFP HIV HIV protease inhibitor HIV protease inhibitors in vitro In vitro assay in-depth analysis Infection inhibit inhibition Inhibition profiling inhibitor inhibitory effect Lopinavir M pro mechanism of action methodology molecular much higher pandemic plasma protease reported reporter required Result Ritonavir SARS-CoV-2 targeting therapy while [DOI] 10.1186/s12985-020-01457-0 PMC 바로가기 [Article Type] Research
Efficacité et innocuité des agents antiviraux contre le SRAS-CoV-2, selon des données d’études sur la COVID-19 et d’autres infections virales aiguës : revue systématique et méta-analyseEfficacité et innocuité des agents antiviraux contre le SRAS-CoV-2, selon des données d'études sur la COVID-19 et d'autres 감염 바이러스 백신 : revue systématique et méta-analyseMeta-Analysis Published on 2020-11-232022-09-11 Journal: CMAJ : Canadian Medical Association journal = jour [Category] SARS, 치료제, [키워드] Arbidol augmentation base CENTRAL Chloroquine Chongqing CNKI Controlled controlled trials coronavirus Coronavirus 2019 COVID-19 Favipiravir forme Hydroxychloroquine Infection Lopinavir Lopinavir/ritonavir nous Patient Ritonavir SinoMed SRAS-CoV-2 syndrome umifenovir VIP [DOI] 10.1503/cmaj.200647-f PMC 바로가기 [Article Type] Meta-Analysis
Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression AnalysisCOVID-19에 감염된 환자의 중증 질병 및 치료 효능에 대한 위험 요인: 체계적인 검토, 메타 분석 및 메타 회귀 분석Meta-Analysis Published on 2020-11-192022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 임상, [키워드] acute respiratory distress acute respiratory distress syndrome Admission Alanine alanine aminotransferase ARDS aspartate Aspartate transaminase benefit clinical feature conducted coronavirus coronavirus disease Coronavirus disease 2019 Corticosteroids COVID-19 Efficacy elevated elevated lactate dehydrogenase Factor ICU ICU admission intensive care intensive care unit Lactate lactate dehydrogenase LDH leukocyte Lopinavir Lopinavir-ritonavir Meta-analysis meta-regression Mortality outcomes pandemic pandemic spread Patient Pooled rates predicted predictor present procalcitonin reported respiratory distress Respiratory distress syndrome review risk risk factor Ritonavir severe severe disease Spread syndrome systematic review Treatment [DOI] 10.1093/cid/ciaa576 PMC 바로가기 [Article Type] Meta-Analysis
Therapeutic options in the treatment of severe acute respiratory syndrome coronavirus 2 in pregnant patient임산부의 중증급성호흡기증후군 코로나바이러스 2 치료에 대한 치료 옵션Review Published on 2020-11-012022-09-11 Journal: American journal of obstetrics & gynecology MFM [Category] SARS, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addressed anticoagulation Case series case sery Chloroquine Complication Contact contact with convalescent convalescent plasma coronavirus Corticosteroids exclusion healthcare Hydroxychloroquine Inclusion Infection inhibitors interleukin interleukin-6 interleukin-6 inhibitors Lopinavir Lopinavir-ritonavir pandemic Patient plethora pregnant pregnant patient pregnant patients pregnant population Prevent randomized control trial Randomized control trials Remdesivir respiratory Ritonavir severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Side effect therapeutic option therapeutic options treat Treatment Trial [DOI] 10.1016/j.ajogmf.2020.100224 PMC 바로가기 [Article Type] Review
Clinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infectionSARS-CoV-2 감염으로 입원한 간이식 환자의 임상적 특징 및 관리Case Reports Published on 2020-11-012022-09-11 Journal: Clinics and research in hepatology and gastroenter [Category] SARS, 치료제, [키워드] Admission affected Case report cefepime Characteristics cirrhosis clinical clinically conditions cough COVID-19 CT scan CT-scan emergency department Evolution of SARS-CoV-2 Fever general condition General population HCV Hepatocellular carcinoma Hydroxychloroquine Immunosuppressed immunosuppressed patient immunosuppressed patients Immunosuppression interstitial pneumonia Isolation limitations liver Liver injury Liver transplantation liver transplanted patient Lopinavir Lopinavir/ritonavir low-dose Low-dose CT scan. management meropenem moderate moderate to severe NASH O2 Saturation outcome Patient patients positive progression pulmonary pulmonary infiltrates reduced referred to remained replaced REPLACED BY resolved Ritonavir SARS-COV-2 infection significantly specimen subpleural the patient Treatment [DOI] 10.1016/j.clinre.2020.05.014 PMC 바로가기 [Article Type] Case Reports
Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: A retrospective study in two designated hospitals in Anhui, ChinaLopinavir/ritonavir 및 인터페론 병용 요법은 COVID-19 환자의 바이러스 배출 기간을 단축하는 데 도움이 될 수 있습니다.Multicenter Study Published on 2020-11-012022-09-11 Journal: Journal of medical virology [Category] 치료제, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition age analyzed Antiviral treatment Associated factors China collected combination therapy coronavirus coronavirus disease coronavirus disease-2019 COVID-19 Cox proportional hazard Cox proportional hazards model cross-sectional study Delayed electronic medical records Factor hazard ratio help hospital Hospital stay Hospitalization IFN-α illness onset independent initial interferon Interferon-α interquartile range IQR Laboratory laboratory-confirmed Laboratory-confirmed COVID-19 Lopinavir Lopinavir/ritonavir male median median time medical costs medical records nothing outcome outcomes Patient patients Prolonged prolonged viral shedding proportional hazards model respiratory Retrospective cross-sectional study Retrospective study Ritonavir RNA SARS-CoV-2 SARS-CoV-2 RNA severe acute respiratory syndrome Coronavirus severity of COVID-19 shedding the mean the median Treatment Viral viral shedding [DOI] 10.1002/jmv.26127 PMC 바로가기 [Article Type] Multicenter Study
Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approachResearch article Published on 2020-11-012022-10-05 Journal: Toxicology and applied pharmacology [Category] SARS, 치료법, [키워드] affected Anti-COVID-19 Therapy antibiotic antiretroviral drugs apoA1 approach Autoimmune diseases Azithromycin BCL2L1 benefit candidate drug CCL2 Chloroquine chloroquine/hydroxychloroquine clinical condition Combination Comparative COVID-19 CTSB CXCL8 CYP3A4 Cytoscape software demonstrated Diseases disorders downregulated drug drug combination dyslipidaemia expected expression greater ICAM1 IL1B IL6 immune response improvement in silico in silico Approach infected patient Inflammation involved lipid metabolism Lopinavir Patient pharmacological problems Research risk Ritonavir Safety SARS-CoV-2 therapy TNF Toxicogenomics Treatment was used [DOI] 10.1016/j.taap.2020.115237 [Article Type] Research article